Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
BörsenkürzelVRAX
Name des UnternehmensVirax Biolabs Group Ltd
IPO-datumJul 14, 2022
CEOMr. James Foster
Anzahl der mitarbeiter19
WertpapierartOrdinary Share
GeschäftsjahresendeJul 14
AddresseBiocity Glasgow
StadtLONDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlML1 5UH
Telefon4402077887414
Websitehttps://www.viraxbiolabs.com
BörsenkürzelVRAX
IPO-datumJul 14, 2022
CEOMr. James Foster
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten